Attributes Necessary for a Commercially Successful Metabolic Peptide
Andrew Young
Head Endocrine Biology, Glaxo Smith Kline
Dr Andrew Young received his M.B., Ch.B. (M.D.) and his Ph.D. in Physiology from the University of Auckland, New Zealand. Following clinical practice with the Auckland Hospital Board, he spent time at various research institutions including University of Auckland, National Institutes of Health and at Bad Nauheim, Germany as a Max-Planck Fellow.
In 1989 Dr. Young joined Amylin Pharmaceuticals Inc in San Diego as the founding physiologist eventually assuming position of VP Research and Senior Research Fellow. He lead the physiologic characterization of the hormone, amylin and the analog pramlintide and for the acquisition and preclinical development of exenatide, launched as BYETTA.
Since December 2008, he has been head of Enteroendocrine Biology at GlaxoSmithKline, RTP, NC, focusing upon peptidic and other therapies for metabolic diseases.
Dr Young is the holder of over 40 patents and has published over 100 papers, 200 abstracts and 20 book chapters/books.